EUVIMEDEUVIMED entdecken
Beobachtungsstudie

The Impact of Semaglutide on Weight Loss and Inflammation in People with HIV. An Observational Prospective Study in Greek Population

Vasileios Petrakis, Petros Rafailidis, Maria Panopoulou, Theocharis Konstantinidis, Andreas G Tsantes iD, Nikoleta Babaka, Dimitrios Papazoglou, Periklis Panagopoulos

Experimental and Clinical Endocrinology & Diabetes · 2026-02 · 134 (02) · 29-35

DOI: 10.1055/a-2737-6227 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Experimental and Clinical Endocrinology & Diabetes, online erschienen am 05.03.2026. Verfasst von Vasileios Petrakis und 7 weiteren Autor:innen. Beteiligte Einrichtung: 2nd University Department of Internal Medicine, Department of Infectious Diseases, Democritus University of Thrace, General University Hospital of Al…. Hauptthemen laut MEDLINE: Weight Loss, HIV Infections, Glucagon-Like Peptides, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The existing literature on the effects of semaglutide in people with HIV (PWH) and diabetes mellitus remains limited. In this study, the effects of semaglutide on weight control and inflammation in PWH were evaluated. This is a prospective observational study that included PWH with type 2 diabetes mellitus monitored at the HIV Unit of the University General Hospital of Alexandroupolis and a matched control group of non-HIV individuals. Demographic, anthropometric, and clinical characteristics, including HIV-related data and comorbidities, were reported. All participants received semaglutide with a gradual dose increase to 1 mg once weekly. Body Mass Index (BMI), glycosylated haemoglobin (HbA1c), and inflammatory markers (IL-6, TNF, hsCRP, sCD14, CD4/CD8 ratio) were recorded at baseline and at 6, 12, 18, and 24 months. Fifty participants (PWH: n=25; non-HIV: n=25) were included. At baseline, the mean BMI was 35.2±8.0 kg/m2 for PWH and 36.1±6.0 kg/m2 for non-HIV controls. Semaglutide treatment resulted in significant and sustained weight loss in both groups (p35 kg/m2. Glycemic control also improved significantly, with mean HbA1c decreasing from 7.7%±1.23 to 5.2%±1.02 in PWH (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Weight LossHIV InfectionsGlucagon-Like PeptidesDiabetes Mellitus, Type 2InflammationHypoglycemic AgentsHumansFemaleMaleMiddle AgedGreeceAdultProspective StudiesGlycated Hemoglobin

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsGlycated Hemoglobinhemoglobin A1c protein, human

Autor:innen und Institutionen

  • 2nd University Department of Internal Medicine, Department of Infectious Diseases, Democritus University of Thrace, General University Hospital of Alexandroupolis, Alexandroupolis, Greece.
  • 2nd University Department of Internal Medicine, Department of Infectious Diseases, University General Hospital Alexandroupolis, Democritus University Thrace, General University Hospital of Evros Sector of Alexandroupoli…
  • Univeristy Laboratory of Microbiology, Democritus University Thrace, General University Hospital of Evros Sector of Alexandroupolis, Alexandroupolis, Greece.
  • Laboratory of Haematology and Blood Bank Unit, School of Medicine, National and Kapodistrian University of Athens, Panepistemiako Geniko Nosokomeio Attikon, Athens, Greece.
  • Microbiology Department, Agios Savvas General Cancer and Oncology Hospital of Athens, Athens, Greece.

ORCID-Profile: Andreas G Tsantes

Zitieren

APA

Petrakis, V., Rafailidis, P., Panopoulou, M., Konstantinidis, T., Tsantes, A. G., Babaka, N., Papazoglou, D., & Panagopoulos, P. (2026). The Impact of Semaglutide on Weight Loss and Inflammation in People with HIV. An Observational Prospective Study in Greek Population. Experimental and Clinical Endocrinology & Diabetes, 134(02), 29-35. https://doi.org/10.1055/a-2737-6227

Vancouver

Petrakis V, Rafailidis P, Panopoulou M, Konstantinidis T, Tsantes AG, Babaka N, et al. The Impact of Semaglutide on Weight Loss and Inflammation in People with HIV. An Observational Prospective Study in Greek Population. Experimental and Clinical Endocrinology & Diabetes. 2026;134(02):29-35. doi:10.1055/a-2737-6227

BibTeX
@article{Petrakis2026,
  author = {Petrakis, Vasileios and Rafailidis, Petros and Panopoulou, Maria and Konstantinidis, Theocharis and Tsantes, Andreas G and Babaka, Nikoleta and Papazoglou, Dimitrios and Panagopoulos, Periklis},
  title = {The Impact of Semaglutide on Weight Loss and Inflammation in People with HIV. An Observational Prospective Study in Greek Population},
  journal = {Experimental and Clinical Endocrinology & Diabetes},
  year = {2026},
  volume = {134},
  number = {02},
  pages = {29--35},
  doi = {10.1055/a-2737-6227}
}
Kostenlos starten →